Cover Image
市場調查報告書

皮膚T-細胞淋巴瘤(蕈樣徽菌病):開發中產品分析

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213067
出版日期 內容資訊 英文 195 Pages
訂單完成後即時交付
價格
Back to Top
皮膚T-細胞淋巴瘤(蕈樣徽菌病):開發中產品分析 Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015
出版日期: 2015年09月16日 內容資訊: 英文 195 Pages
簡介

皮膚T-細胞淋巴瘤 (CTCL) 是淋巴增生性疾病的一種,指的是皮膚上腫瘤性T淋巴球局部化的症狀。主要的症狀·前兆有紅皮疹狀的斑點,及皮膚的發癢和疼,斑點的膨脹 (斑塊),腫包等。主要的治療方法有化療和放射治療等。

本報告提供全球各國治療皮膚T-細胞淋巴瘤所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

皮膚T-細胞淋巴瘤概要

治療藥的開發

  • 皮膚T-細胞淋巴瘤開發中產品:概要
  • 皮膚T-細胞淋巴瘤開發中產品:比較分析

各企業開發中的皮膚T-細胞淋巴瘤治療藥

大學/研究機關研究中的皮膚T-細胞淋巴瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

皮膚T-細胞淋巴瘤治療藥:開發中的產品一覽 (各企業)

皮膚T-細胞淋巴瘤治療藥:研究中的產品一覽 (大學/研究機關別)

皮膚T-細胞淋巴瘤開發治療藥的企業

  • 4SC AG 20
  • Affimed Therapeutics AG
  • Chipscreen Biosciences Ltd
  • Cornerstone Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Eisai
  • Galderma S.A.
  • Innate Pharma SA
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • Kyowa Hakko Kirin
  • MedImmune, LLC
  • Neumedicines Inc.
  • Novartis AG
  • OncoSec Medical Inc.
  • Onyx Pharmaceuticals, Inc.
  • Sanofi
  • Seattle Genetics, Inc.
  • Soligenix, Inc.
  • Taiwan Liposome Company, Ltd.
  • TetraLogic Pharmaceuticals

皮膚T-細胞淋巴瘤:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • A-dmDT390-bisFv
    • 產品概要
    • 作用機制
    • 研究開發 (R&D) 的發展情形
  • AFM-13
  • alemtuzumab
  • AMP-224
  • Angeloxin
  • bexarotene
  • brentuximab vedotin
  • carfilzomib
  • CIGB-128
  • CPI-613
  • CS-055
  • DNA IL-12
  • everolimus
  • IPH-4102
  • mogamulizumab
  • NMIL-121
  • quisinostat hydrochloride
  • resminostat
  • sapacitabine
  • selinexor
  • SGX-301
  • SHP-141
  • trifarotene
  • vinorelbine tartrate

皮膚T-細胞淋巴瘤治療藥:開發中產品的最新趨勢

皮膚T-細胞淋巴瘤治療藥:開發暫停的產品

皮膚T-細胞淋巴瘤治療藥:開發中止的產品

皮膚T-細胞淋巴瘤相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿 (全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7095IDB

Summary

Global Markets Direct's, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015', provides an overview of the Cutaneous T-Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cutaneous T-Cell Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cutaneous T-Cell Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cutaneous T-Cell Lymphoma Overview
  • Therapeutics Development
    • Pipeline Products for Cutaneous T-Cell Lymphoma - Overview
    • Pipeline Products for Cutaneous T-Cell Lymphoma - Comparative Analysis
  • Cutaneous T-Cell Lymphoma - Therapeutics under Development by Companies
  • Cutaneous T-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • Cutaneous T-Cell Lymphoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Cutaneous T-Cell Lymphoma - Products under Development by Companies
  • Cutaneous T-Cell Lymphoma - Products under Investigation by Universities/Institutes
  • Cutaneous T-Cell Lymphoma - Companies Involved in Therapeutics Development
    • 4SC AG
    • Affimed Therapeutics AG
    • Chipscreen Biosciences Ltd
    • Cornerstone Pharmaceuticals, Inc.
    • Cyclacel Pharmaceuticals, Inc.
    • Eisai Co., Ltd.
    • Galderma S.A.
    • Innate Pharma SA
    • Johnson & Johnson
    • Karyopharm Therapeutics, Inc.
    • Kyowa Hakko Kirin Co., Ltd.
    • MedImmune, LLC
    • Neumedicines Inc.
    • Novartis AG
    • OncoSec Medical Inc.
    • Onyx Pharmaceuticals, Inc.
    • Sanofi
    • Seattle Genetics, Inc.
    • Soligenix, Inc.
    • Taiwan Liposome Company, Ltd.
    • TetraLogic Pharmaceuticals
  • Cutaneous T-Cell Lymphoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-dmDT390-bisFv - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AFM-13 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alemtuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMP-224 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Angeloxin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bexarotene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brentuximab vedotin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CIGB-128 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CPI-613 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CS-055 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNA IL-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPH-4102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mogamulizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NMIL-121 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • quisinostat hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • resminostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sapacitabine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGX-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-141 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trifarotene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vinorelbine tartrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cutaneous T-Cell Lymphoma - Recent Pipeline Updates
  • Cutaneous T-Cell Lymphoma - Dormant Projects
  • Cutaneous T-Cell Lymphoma - Discontinued Products
  • Cutaneous T-Cell Lymphoma - Product Development Milestones
    • Featured News & Press Releases
      • Aug 04, 2015: Soligenix Receives Orphan Drug Designation from the European Commission for SGX301 as a Treatment for Cutaneous T-Cell Lymphoma
      • Jun 23, 2015: Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma
      • Apr 07, 2015: DSG Partners with Soligenix to Battle Cutaneous T-Cell Lymphoma
      • Jan 07, 2015: FDA Grants Soligenix Fast Track"Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
      • Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
      • Nov 03, 2014: IPH 4102 Preclinical Data Published In Cancer Research
      • Sep 17, 2014: Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
      • Aug 27, 2014: Innate Pharma's IPH4102 Receives Orphan Drug Designation In European Union
      • Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries
      • Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2015
  • Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by 4SC AG, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Galderma S.A., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Innate Pharma SA, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Novartis AG, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by OncoSec Medical Inc., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Sanofi, H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Soligenix, Inc., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2015
  • Cutaneous T-Cell Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Cutaneous T-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015
  • Cutaneous T-Cell Lymphoma - Dormant Projects, H2 2015
  • Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..1), H2 2015
  • Cutaneous T-Cell Lymphoma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2015
  • Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top